Ten years after a US FDA advisory committee called on the agency to require cardiovascular outcomes trials for all type 2 diabetes drug candidates, the agency is reconvening the panel, apparently to consider the ongoing need for, and design of, these studies.
In a Federal Register notice scheduled for publication Sept. 18, FDA announced that the Endocrinologic and Metabolic Drugs Advisory...





